FindTrial
Sign In

FLOT

DRUG6 trials

Sponsors

Kawakubo Hirofumi, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, University of California, Irvine, European Organisation for Research and Treatment of Cancer - EORTC

Conditions

Adenocarcinoma of the StomachEsophageal squamous cell carcinoma Esophageal squamous cell carcinomaEsophagogastric AdenocarcinomaEsophagus AdenocarcinomaGastroEsophageal CancerGastroesophageal Adenocarcinoma

Phase 1

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
RecruitingNCT05733689
University of California, IrvineGastroesophageal Adenocarcinoma
Start: 2025-06-27End: 2027-06-01Target: 20Updated: 2026-03-10
Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment
Not yet recruitingNCT06978062
European Organisation for Research and Treatment of Cancer - EORTCGastroEsophageal Cancer
Start: 2026-02-20End: 2029-09-28Target: 27Updated: 2025-06-05

Phase 2

Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer
CompletedNCT03647969
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestAdenocarcinoma of the Stomach, GastroEsophageal Cancer
Start: 2018-11-07End: 2024-07-19Updated: 2024-08-09
Prospective trial to evaluate the safety and efficacy to treat esophageal cancer using 5-FU, Oxaliplatin, and Docetaxel
Active, not recruitingJPRN-jRCTs031200094
Kawakubo HirofumiEsophageal squamous cell carcinoma Esophageal squamous cell carcinoma
Start: 2020-09-07Target: 60Updated: 2025-07-18
Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma
Active, not recruitingNCT05504720
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestEsophagogastric Adenocarcinoma
Start: 2023-02-13End: 2027-12-31Updated: 2025-06-06
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery
RecruitingNCT05713838
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestEsophagus Adenocarcinoma
Start: 2023-08-28End: 2028-12-31Target: 32Updated: 2024-09-19

Related Papers

First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial
Nature Communications2026-02-27
Phase II study of neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel for resectable esophageal squamous cell carcinoma: Survival analysis.
Journal of Clinical Oncology2026-01-10
Response adapted neoadjuvant therapy in gastric cancer (RANT-GC): A phase Ib feasibility trial.
Journal of Clinical Oncology2026-01-10
Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial.
2025-10-181 citations
Phase II study of neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel for resectable esophageal squamous cell carcinoma.
Journal of Clinical Oncology2025-01-272 citations
Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1, and cT2N0 esophageal adenocarcinoma with indication for radical surgery: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group (IKF-t057/PRESTO trial).
Journal of Clinical Oncology2024-01-203 citations
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)
Frontiers in Oncology2023-10-167 citations
FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase 2 IKF-S628/AIO-STO-0417 (Moonlight) trial of the AIO.
Journal of Clinical Oncology2023-06-012 citations
Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: The randomized phase 2 IKF-S628 Moonlight trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Journal of Clinical Oncology2023-06-011 citations
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy within the prospective phase II IKF-S628/AIO-STO-0417 (MOONLIGHT) trial.
Journal of Clinical Oncology2023-06-01
FOLFOX versus FOLFOX plus nivolumab and ipilimumab administered in parallel or sequentially versus FLOT plus nivolumab administered in parallel in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: A randomized phase 2 trial of the AIO.
Journal of Clinical Oncology2022-06-016 citations
Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase 2 trial of the German Gastric Group of the AIO.
Journal of Clinical Oncology2019-05-204 citations